Oaktree Acquisition Corp. III Life Sciences (OACC) Long-Term Investments (2024 - 2026)

Oaktree Acquisition Corp. III Life Sciences has reported Long-Term Investments for 3 years, with the latest figure at $203.4 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments rose 3.95% year-over-year to $203.4 million; the trailing twelve-month figure through Mar 2026 stood at $203.4 million (up 3.95% YoY), and the FY2025 full-year result was $201.6 million, up 4.12% from the prior year.
• Long-Term Investments for Q1 2026 stood at $203.4 million, up from $201.6 million in the prior quarter.
• The five-year high for Long-Term Investments was $203.4 million in Q1 2026, with the low at $193.6 million in Q4 2024.
• Historically, Long-Term Investments has averaged $198.6 million across 3 years, with a median of $198.7 million in 2025.
• Annual changes were most pronounced in 2025 — Long-Term Investments gained 4.12% — and 2026, when it climbed 3.95%.
• Oaktree Acquisition Corp. III Life Sciences' Long-Term Investments stood at $193.6 million in 2024, then grew by 4.12% to $201.6 million in 2025, then increased by 0.92% to $203.4 million in 2026.
• The last three Long-Term Investments figures came in at $203.4 million (Q1 2026), $201.6 million (Q4 2025), and $199.8 million (Q3 2025), per Business Quant data.